Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis. The primary endpoint was modified Rodnan Skin Score at 12 mo...
Serious postoperative complications and reoperation after carpal tunnel decompression surgery in England: a nationwide cohort analysis
Of the 855 832 initial surgeries, 620 procedures led to a serious complication within 30 days after surgery. The study is the largest national study o...
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial
Inclusion body myositis is most frequent in patients older than 50 years. In this pilot study, we aimed to test the efficacy of sirolimus in patients...
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Flares of worsen...
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Hydroxychloroquine has been shown to inhibit entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into epithelial cells in vitro. Cli...
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
We identified 8540 patients with rheumatic and musculoskeletal diseases who were diagnosed with COVID-19. Risk of hospitalisation was lower in the lat...
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
Belimumab is approved for the treatment of active systemic lupus erythematosus. BASE was a double-blind, randomised, placebo-controlled, phase 4 trial...
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
300 mg of intravenous anifrolumab every 4 weeks added to standard-of-care treatment for patients with systemic lupus erythematosus (SLE) reduced disea...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
